Company intelligence
Genomic Testing Cooperative
Cancer is too complex for partial results. GTC analyzes both DNA and RNA to provide more comprehensive molecular answers
About Genomic Testing Cooperative
Cancer is complex. A partial molecular picture can limit what clinicians know about a patient’s disease. Genomic Testing Cooperative analyzes both DNA and RNA to provide more comprehensive insight into cancer biology, supporting diagnosis, prognosis, monitoring, and precision medicine. Through advanced NGS, AI-enabled interpretation, RNA innovation, and a cooperative model for hospitals and laboratories, GTC is helping move cancer diagnostics toward a more complete, molecular-first future. Why GTC? Comprehensive DNA and RNA Testing GTC analyzes both DNA and RNA to provide broader molecular insight than limited or DNA-only approaches. More Complete Biomarker Insight GTC’s testing is designed to identify clinically relevant biomarkers that may help inform diagnosis, prognosis, monitoring, and precision medicine.
Verified activity
Signals from Genomic Testing Cooperative
2 published signals
Operations & Supply
Genomic Testing Cooperative will be closed on Monday for the holiday and open for business on Tuesday.
Reported by Genomic Testing Cooperative
Research & Knowledge
Genomic Testing Cooperative published consensus guidelines recommending CSF liquid biopsy for some tumor types.
Reported by Genomic Testing Cooperative